Investor Presentaiton
Accelerating commercial progress
Mar- Jul 22
31 Aug 22
30 Sep 22
19 Oct 22
4DMedical™
25 Oct 22
Making
significant
progress across
all areas of
operations
Major success
as Vanderbilt
'burn pit' trial
hits primary
endpoint
Continuing
engagement
with legislators,
advocates and
the VA
4DMedical
progress
towards full
reimbursement
in the U.S.
4DMedical
release of
CT LVASTM in
Australia
•
XV Scanner unveiled at Prince
of Wales Hospital in Sydney.
•
.
US clinical pilot at Providence
St Joseph commenced.
Johns Hopkins COPD clinical
trial results presented at ATS.
Three-year national contract
•
signed with I-MED.
•
XV TechnologyⓇ validated
through US clinical trials.
•
Facilitates commercial
prospects in the US.
•
Supports significant
opportunities with the
already built VA and DoD
relationships.
Increase research benefiting
veterans exposed to burn pits
and toxic air.
Collaborating with advocates,
including Rosie Torres of Burn
Pits 360.
Enabling the PACT Act to
reach its full potential, by
scaling up VA evaluation and
diagnosis processes without
an invasive biopsy.
AMA accepts XV LVASⓇ
application to establish a new
CPT code.
Cat III code is a milestone for
XV LVASⓇ to become a fully
commercialised reimbursable
product in the U.S.
Expands 4DMedical's product
visibility in the broader U.S.
payer space.
Strong news flow pipeline across all areas of operations
•
4DMedical releases
Computed Tomography Lung
Ventilation Analysis Software
(CT LVAS™).
Expands patient accessibility
by leveraging readily
available CT hardware.
Seamless integration enabled
through the existing I-MED
partnership.
4DMedical Limited | Investor Presentation | November 2022
3View entire presentation